ArticleFrontiers in pharmacology2026
Knowledge, attitudes, and perceptions of pharmacogenetic testing in swiss community pharmacies: a mixed-methods study among physicians, pharmacists, and the general public.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenetic testing represents a promising approach for the individualization of drug therapies. Nevertheless, its integration within the Swiss healthcare system remains limited to date. This study aimed to explore the knowledge, attitudes, and perceptions of physicians, pharmacists, and the general public toward PGx testing conducted in community pharmacy settings in Switzerland. A mixed-methods design was employed. Structured questionnaires were used to assess participants' knowledge, perceived clinical utility, and anticipated barriers to implementation, while semi-structured interviews allowed for a more in-depth exploration of individual perspectives. Quantitative data were analyzed using descriptive statistics, consistent with the exploratory scope of the study, and qualitative data were processed through thematic analysis. A total of 332 participants completed the questionnaire, including 100 physicians, 122 pharmacists, and 110 members of the general public, and 26 took part in the interviews. PGx testing was perceived as clinically relevant across all stakeholder groups. The main barriers identified included insufficient specialized training, the absence of standardized guidelines, financial constraints, and ethical concerns. The need for strengthened interprofessional collaboration was also highlighted. This study sheds light on the key challenges associated with the integration of PGx testing in community pharmacy practice in Switzerland, spanning educational, organizational, and ethical dimensions. The findings should be interpreted within a descriptive framework, as the study design does not support causal or inferential conclusions. To enable successful implementation, it appears essential to develop targeted training programs, structure interprofessional collaboration, and establish robust policies for the protection of genetic data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.